Biocon Limited has informed the Exchange regarding a press release dated Jun 27, 2025, titled "Biocon Biologics Receives Health Canada Approval for Yesafili (aflibercept); First Global Launch Scheduled for July 2025".
Biocon Limited Press Release Jun 27 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Biocon
- Press Release Jun 24 2025
- Press Release Jun 20 2025
- Press Release Jun 09 2025
- Press Release May 08 2025
- Press Release May 05 2025
Later from Biocon
- Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025
- Biocon Limited Press Release Jun 30 2025
- Biocon Limited Press Release Jul 03 2025
- Biocon Limited Press Release Jul 07 2025
- Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon